PMID- 28418203
OWN - NLM
STAT- MEDLINE
DCOM- 20180814
LR  - 20221207
IS  - 1753-0407 (Electronic)
IS  - 1753-0407 (Linking)
VI  - 10
IP  - 1
DP  - 2018 Jan
TI  - Effectiveness of vildagliptin as add-on to metformin monotherapy among 
      uncontrolled type 2 diabetes mellitus patients in a real-world setting.
PG  - 68-72
LID - 10.1111/1753-0407.12560 [doi]
AB  - BACKGROUND: Vildagliptin is a dipeptidyl peptidase-4 inhibitor commonly used as a 
      dual oral agent with metformin, thiazolidinediones, or sulfonylurea for the 
      treatment of type 2 diabetes mellitus (T2DM). The efficacy of dual therapy with 
      vildagliptin and metformin has been established in randomized controlled trials, 
      but there is little evidence from observational studies. The aims of the present 
      study were to evaluate the effectiveness of vildagliptin as an add-on therapy to 
      metformin in reducing HbA1c and its affects on body weight and blood lipids in a 
      real-life setting. METHODS: Included in the present retrospective cohort were 
      T2DM patients (n = 345) who were uncontrolled on metformin monotherapy and 
      intensified treatment with vildagliptin. The efficacy of at least 90 days of dual 
      therapy with vildagliptin and metformin in reducing HbA1c levels, as well as 
      changes in blood lipids and body weight, were evaluated. RESULTS: After 180 days 
      (range 90-365 days) from the index date with a mean daily dose of 92 mg 
      vildagliptin, HbA1c was significantly (P < 0.001) reduced by an average of 0.9% 
      (95% confidence interval -1.0%, -0.7%). The absolute reduction in HbA1c was 
      positively associated with baseline HbA1c levels. In addition to HbA1c, a modest 
      but significant (P < 0.05) decrement was also calculated in the patients' body 
      weight and blood lipids. CONCLUSIONS: The present analysis of real-world data 
      corroborates the results of previous randomized controlled trials indicating that 
      add-on therapy with vildagliptin in uncontrolled patients on metformin 
      monotherapy is associated with a significant improvement in the control of HbA1c.
CI  - (c) 2017 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and John 
      Wiley & Sons Australia, Ltd.
FAU - Melzer Cohen, Cheli
AU  - Melzer Cohen C
AD  - Maccabi Institute for Research and Innovation, Maccabi Healthcare Services, Tel 
      Aviv, Israel.
FAU - Davis, Carla
AU  - Davis C
AD  - Maccabi Institute for Research and Innovation, Maccabi Healthcare Services, Tel 
      Aviv, Israel.
FAU - Shalev, Varda
AU  - Shalev V
AD  - Maccabi Institute for Research and Innovation, Maccabi Healthcare Services, Tel 
      Aviv, Israel.
AD  - Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Chodick, Gabriel
AU  - Chodick G
AD  - Maccabi Institute for Research and Innovation, Maccabi Healthcare Services, Tel 
      Aviv, Israel.
AD  - Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
LA  - eng
PT  - Journal Article
DEP - 20170522
PL  - Australia
TA  - J Diabetes
JT  - Journal of diabetes
JID - 101504326
RN  - 0 (Blood Glucose)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Nitriles)
RN  - 0 (Pyrrolidines)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 9100L32L2N (Metformin)
RN  - I6B4B2U96P (Vildagliptin)
RN  - PJY633525U (Adamantane)
SB  - IM
MH  - Adamantane/*analogs & derivatives/therapeutic use
MH  - Blood Glucose/*metabolism
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Glycated Hemoglobin/*analysis
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Male
MH  - Metformin/*therapeutic use
MH  - Middle Aged
MH  - Nitriles/*therapeutic use
MH  - Pyrrolidines/*therapeutic use
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Vildagliptin
OTO - NOTNLM
OT  - 2型糖尿病
OT  - dipeptidyl peptidase 4 inhibitors
OT  - metformin
OT  - type 2 diabetes mellitus
OT  - vildagliptin
OT  - 二甲双胍
OT  - 二肽基肽酶-4抑制剂
OT  - 维格列汀
EDAT- 2017/04/19 06:00
MHDA- 2018/08/15 06:00
CRDT- 2017/04/19 06:00
PHST- 2016/07/11 00:00 [received]
PHST- 2017/01/08 00:00 [revised]
PHST- 2017/04/06 00:00 [accepted]
PHST- 2017/04/19 06:00 [pubmed]
PHST- 2018/08/15 06:00 [medline]
PHST- 2017/04/19 06:00 [entrez]
AID - 10.1111/1753-0407.12560 [doi]
PST - ppublish
SO  - J Diabetes. 2018 Jan;10(1):68-72. doi: 10.1111/1753-0407.12560. Epub 2017 May 22.